Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis

Journal of Nephrology

Volumn 25, Issue 6, 2012, Pages 989-995

  Toyoda, Masao ^a   Kimura, Moritsugu ^a   Yamamoto, Naoyuki ^a   Miyauchi, Masaaki ^a   Umezono, Tomoya ^a   Suzuki, Daisuke ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hemodialysis; Hypoglycemia; Insulin glargine; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; PIG INSULIN; RECOMBINANT HUMAN INSULIN; SHORT ACTING INSULIN;

ADVERSE OUTCOME; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL EVALUATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMATOCRIT; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG SUBSTITUTION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84870597571     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000081     Document Type: Article

References (16)

1. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis. 2007;50(5):865-879.
2. Iglesias P, Díez JJ. Insulin therapy in renal disease. Diabetes Obes Metab. 2008;10(10):811-823.
3. Fritsche A, Larbig M, Owens D, Häring HU; GINGER study group. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes: results of the GINGER study. Diabetes Obes Metab. 2010;12(2):115-123.
4. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician. 2004;70(3):489-500.
5. Seino Y, Nanjo K, Tajima N, et al; The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest. 2010;1(5):212-228.
6. Hayashino Y, Fukuhara S, Akiba T, et al. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia. 2007;50(6):1170-1177.
7. Kalantar-Zadeh K, Kopple JD, Regidor DL, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care. 2007;30(5):1049-1055.
8. Oomichi T, Emoto M, Tabata T, et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care. 2006;29(7): 1496-1500.
9. Rubenstein AH, Mako ME, Horwitz DL. Insulin and the kidney. Nephron. 1975;15(3-5):306-326.
10. 1c levels in patients with chronic renal failure on hemodialysis. Intern Med. 1998;37(10): 826-830.
11. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-3086.
12. Saloranta C, Hershon K, Ball M, Dickinson S, Holmes D. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab. 2002;87(9):4171-4176.
13. Takamura T, Sakurai M, Nakamura M, et al. Factors associated with improvement of fasting plasma glucose level by mealtime dosing of a rapid-acting insulin analog in type 2 diabetes. Diabetes Res Clin Pract. 2007;75(3):278-284.
14. Tanaka Y, Atsumi Y, Asahina T, et al. Usefulness of revised fasting plasma glucose criterion and characteristics of the insulin response to an oral glucose load in newly diagnosed Japanese diabetic subjects. Diabetes Care. 1998;21(7):1133-1137.
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
16. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001;24(4):631-636.